The fluoroquinolones after ciprofloxacin and ofloxacin.
Hooper
D C
DC
Harvard Medical School, Division of Infectious Diseases, Massachusetts General Hospital, Boston, USA.
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D024841:Fluoroquinolones; D006801:Humans; D009287:Naphthyridines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy; D015231:Sexually Transmitted Diseases, Bacterial / Q000188:drug therapy; D017192:Skin Diseases, Bacterial / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D010879:Piperazines; C080163:trovafloxacin; D015242:Ofloxacin; C075375:grepafloxacin; C061363:sparfloxacin